Leerink Swann Research Analysts Increase Earnings Estimates for Seres Therapeutics, Inc. (NASDAQ:MCRB)
Seres Therapeutics, Inc. (NASDAQ:MCRB) – Investment analysts at Leerink Swann increased their Q3 2017 earnings estimates for shares of Seres Therapeutics in a research report issued on Thursday. Leerink Swann analyst J. Schwartz now anticipates that the biotechnology company will post earnings of ($0.23) per share for the quarter, up from their prior forecast of ($0.73). Leerink Swann also issued estimates for Seres Therapeutics’ Q4 2017 earnings at ($0.74) EPS, FY2017 earnings at ($2.30) EPS, FY2018 earnings at ($2.49) EPS and FY2019 earnings at ($2.24) EPS.
Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.59) by $0.10. The business had revenue of $3 million during the quarter, compared to the consensus estimate of $3 million. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 73.45%. The company’s revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.70) EPS.
Several other equities research analysts have also weighed in on MCRB. Canaccord Genuity set a $20.00 price objective on Seres Therapeutics and gave the stock a “buy” rating in a report on Thursday, May 4th. Cantor Fitzgerald set a $16.00 price objective on Seres Therapeutics and gave the stock a “buy” rating in a report on Thursday, May 4th. Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a report on Friday, May 19th. Zacks Investment Research raised Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Wednesday, July 5th. Finally, BidaskClub raised Seres Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $16.17.
Shares of Seres Therapeutics (NASDAQ MCRB) opened at 13.69 on Monday. The company’s market cap is $552.94 million. Seres Therapeutics has a 12 month low of $8.85 and a 12 month high of $15.09. The stock has a 50 day moving average of $11.94 and a 200-day moving average of $10.51.
A number of hedge funds and other institutional investors have recently bought and sold shares of MCRB. State Street Corp raised its position in Seres Therapeutics by 6.4% in the fourth quarter. State Street Corp now owns 275,970 shares of the biotechnology company’s stock worth $2,733,000 after buying an additional 16,671 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Seres Therapeutics by 35.0% in the fourth quarter. Renaissance Technologies LLC now owns 400,300 shares of the biotechnology company’s stock worth $3,963,000 after buying an additional 103,800 shares during the period. Teachers Advisors LLC increased its stake in shares of Seres Therapeutics by 43.5% in the fourth quarter. Teachers Advisors LLC now owns 41,101 shares of the biotechnology company’s stock worth $407,000 after buying an additional 12,462 shares during the period. Bank of Montreal Can increased its stake in shares of Seres Therapeutics by 33.7% in the first quarter. Bank of Montreal Can now owns 19,144 shares of the biotechnology company’s stock worth $216,000 after buying an additional 4,829 shares during the period. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Seres Therapeutics during the first quarter worth about $136,000. 75.52% of the stock is owned by institutional investors and hedge funds.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.